MX351062B - Proteinas de fusion para el tratamiento del snc. - Google Patents

Proteinas de fusion para el tratamiento del snc.

Info

Publication number
MX351062B
MX351062B MX2012003710A MX2012003710A MX351062B MX 351062 B MX351062 B MX 351062B MX 2012003710 A MX2012003710 A MX 2012003710A MX 2012003710 A MX2012003710 A MX 2012003710A MX 351062 B MX351062 B MX 351062B
Authority
MX
Mexico
Prior art keywords
cns
treatment
fusion proteins
blocking
activity
Prior art date
Application number
MX2012003710A
Other languages
English (en)
Inventor
O Caggiano Anthony
Iaci Jenifer
P Zimber Michael
A Gruskin Elliott
Roy Garci
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of MX351062B publication Critical patent/MX351062B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a composiciones capaces de usarse en el tratamiento de lesiones de la médula espinal y trastornos relacionados del sistema nervioso central (SNC), y en particular, composiciones que incluyen moléculas que degradan proteoglicanos y composiciones capaces de bloquear y/o de superar la actividad de moléculas inhibidoras del crecimiento neuronal, así como proteínas de fusión que incluyen un dominio de degradación de proteoglicanos y un dominio capaz de bloquear y/o superar la actividad de moléculas inhibidoras del crecimiento neuronal.
MX2012003710A 2003-05-16 2004-05-17 Proteinas de fusion para el tratamiento del snc. MX351062B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47130003P 2003-05-16 2003-05-16
US47123603P 2003-05-16 2003-05-16
US47123903P 2003-05-16 2003-05-16
US47437203P 2003-05-29 2003-05-29
PCT/US2004/015661 WO2004110359A2 (en) 2003-05-16 2004-05-17 Fusion proteins for the treatment of cns

Publications (1)

Publication Number Publication Date
MX351062B true MX351062B (es) 2017-09-29

Family

ID=33556640

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012003710A MX351062B (es) 2003-05-16 2004-05-17 Proteinas de fusion para el tratamiento del snc.
MXPA05012306A MXPA05012306A (es) 2003-05-16 2004-05-17 Proteinas de fusion para el tratamiento del snc.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA05012306A MXPA05012306A (es) 2003-05-16 2004-05-17 Proteinas de fusion para el tratamiento del snc.

Country Status (7)

Country Link
EP (3) EP1646353A4 (es)
JP (5) JP5399612B2 (es)
AU (1) AU2004247025B8 (es)
CA (1) CA2525782C (es)
ES (1) ES2831031T3 (es)
MX (2) MX351062B (es)
WO (1) WO2004110359A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666852B2 (en) * 2002-04-22 2010-02-23 Agenta Biotechnologies, Inc. Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide
DE60336341D1 (de) 2002-05-04 2011-04-21 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
ES2887949T3 (es) 2003-05-16 2021-12-29 Acorda Therapeutics Inc Mutantes degradantes de proteoglicanos para el tratamiento del SNC
CA2566731C (en) * 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
CA2623635C (en) 2005-09-26 2013-04-02 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
WO2007132481A2 (en) * 2006-05-12 2007-11-22 Bharat Biotech International Limited Novel thrombolytic molecules and a process therefor
KR101368742B1 (ko) 2006-05-19 2014-02-28 세이가가쿠 고교 가부시키가이샤 뇌손상 개선제
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
JP2010509612A (ja) * 2006-11-14 2010-03-25 ジェネンテック インコーポレイテッド ニューロン再生の活性調節因子
WO2008149428A1 (ja) * 2007-06-05 2008-12-11 Glycoscience Laboratories, Inc. 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
AU2009217606B2 (en) 2008-02-29 2015-03-05 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
AU2015200220A1 (en) * 2008-02-29 2015-02-12 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
CA2845198A1 (en) * 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
US9144601B2 (en) 2011-09-15 2015-09-29 Seikagaku Corporation Skeletal muscle regeneration promoter
GB201322396D0 (en) 2013-12-18 2014-02-05 Univ Nottingham Transduction
US11396529B2 (en) 2020-11-12 2022-07-26 National Sun Yat-Sen University Isolated peptide, anti-cancer medicinal composition including the same and method of specifically reducing or inhibiting activities of cancer cells using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
WO1994025567A1 (en) * 1993-04-23 1994-11-10 American Cyanamid Company CLONING AND EXPRESSION OF THE CHONDROITINASE I AND II GENES FROM $i(P. VULGARIS)
WO1995013091A1 (en) * 1993-11-12 1995-05-18 International Technology Management Associates, Ltd. Methods of repairing connective tissues
JPH07316068A (ja) * 1994-05-25 1995-12-05 Canji Inc 腫瘍サプレッサー融合タンパク質
GB9622500D0 (en) * 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US6171575B1 (en) * 1998-04-06 2001-01-09 Shinichi Okuyama Method of radioisotopic assessment of the integrity and function of the nose-brain barrier
CA2364690A1 (en) * 1999-02-28 2000-10-19 Washington University Novel transduction molecules and methods for using same
ATE407146T1 (de) * 1999-03-16 2008-09-15 Us Gov Health & Human Serv Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion
SE9901428D0 (sv) * 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
EP1544299B1 (en) * 1999-06-08 2008-12-17 Regeneron Pharmaceuticals, Inc. VEGF receptor chimeras for the treatment of eye disorders characterized by vascular permeability
EP1263459A2 (en) * 1999-12-02 2002-12-11 Ibex Technologies, Inc. Attenuation of fibroblast proliferation
US20020142299A1 (en) * 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
CA2367636C (en) * 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
JP4749667B2 (ja) * 2001-08-13 2011-08-17 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 神経組織の修復を促進するための材料および方法
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
US7807618B2 (en) * 2002-05-20 2010-10-05 The Board Of Regents Of The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone and other tissues
EP1530643B1 (en) * 2002-08-15 2011-05-04 Acorda Therapeutics, Inc. Chimeric protein

Also Published As

Publication number Publication date
JP5399612B2 (ja) 2014-01-29
WO2004110359A2 (en) 2004-12-23
EP1646353A4 (en) 2008-06-04
EP3210999B1 (en) 2020-08-26
EP2354155A2 (en) 2011-08-10
JP2020111578A (ja) 2020-07-27
AU2004247025B2 (en) 2011-06-23
EP3210999A1 (en) 2017-08-30
JP6913428B2 (ja) 2021-08-04
WO2004110359A9 (en) 2006-02-16
JP6141571B2 (ja) 2017-07-12
JP2007516229A (ja) 2007-06-21
CA2525782C (en) 2019-02-05
JP2014221793A (ja) 2014-11-27
AU2004247025A1 (en) 2004-12-23
MXPA05012306A (es) 2006-04-18
WO2004110359A3 (en) 2006-08-17
EP2354155B1 (en) 2017-05-03
EP1646353A2 (en) 2006-04-19
ES2831031T3 (es) 2021-06-07
AU2004247025B8 (en) 2011-06-30
JP2013049677A (ja) 2013-03-14
JP5656314B2 (ja) 2015-01-21
JP2017125035A (ja) 2017-07-20
CA2525782A1 (en) 2004-12-23
EP2354155A3 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
MX351062B (es) Proteinas de fusion para el tratamiento del snc.
IL173123A0 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
AU2003249983A1 (en) Piperidines useful for the treatment of central nervous system disorders
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
HRP20020593A2 (en) Brain, spinal and nerve injury treatment
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
EP1701715A4 (en) ZEAXANTHINE FORMULATIONS WITH ADDITIONAL EYEGATIVE NUTRIENTS FOR THE PROTECTION OF EYE HEALTH AND FOR THE TREATMENT OF EYE DISEASES
WO2004006853A3 (en) Treatment and prophylaxis with 4-1bb-binding agents
HRP20031071A2 (en) Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
WO2007028151A3 (en) Surgical devices and related methods thereof
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
IL176453A0 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
WO2006138316A3 (en) Methods for delivering molecules to the central nervous system
WO2000071102A3 (en) Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
WO2004021992A3 (en) Delivery of therapeutics to the brain and spinal cord
DE602004013540D1 (de) Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen
WO2001082954A3 (en) Ceruloplasmin and uses thereof in neurodegenerative related conditions
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases